Logo image
Sign in
Anaplastic Thyroid Carcinoma, Version 2.2015
Journal article   Open access  Peer reviewed

Anaplastic Thyroid Carcinoma, Version 2.2015

Robert I. Haddad, William M. Lydiatt, Douglas W. Ball, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Megan Haymart, …
Journal of the National Comprehensive Cancer Network, Vol.13(9), pp.1140-1150
09/01/2015
PMID: 26358798

Abstract

Life Sciences & Biomedicine Oncology Science & Technology
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.
url
https://doi.org/10.6004/jnccn.2015.0139View
Published (Version of record) Open

Metrics

1 Record Views

Details